Recent developments and highlights in biomarkers in allergic diseases and asthma

Ibon Eguíluz-Gracia, Tunn Ren Tay, Mark Hew, María Marta Escribese, Domingo Barber, Robyn E. O'Hehir, María José Torres

Research output: Contribution to journalReview ArticleResearchpeer-review

13 Citations (Scopus)

Abstract

The potential of precision medicine in allergy and asthma has only started to be explored. A significant clarification in the pathophysiology of rhinitis, chronic rhinosinusitis, asthma, food allergy and drug hypersensitivity was made in the last decade. This improved understanding led to a better classification of the distinct phenotypes and to the discovery of new drugs such as biologicals, targeting phenotype-specific mechanisms. Nevertheless, many conditions remain poorly understood such as non-eosinophilic airway diseases or non-IgE–mediated food allergy. Moreover, there is a need to predict the response to specific therapies and the outcome of drug and food provocations. The identification of patients at risk of progression towards severity is also an unmet need in order to establish adequate preventive or therapeutic measures. The implementation of precision medicine in the clinical practice requires the identification of phenotype-specific markers measurable in biological matrices. To become useful, these biomarkers need to be quantifiable by reliable systems, and in samples obtained in an easy, rapid and cost-efficient way. In the last years, significant research resources have been put in the identification of valid biomarkers for asthma and allergic diseases. This review summarizes these recent advances with focus on the biomarkers with higher clinical applicability.

Original languageEnglish
Pages (from-to)2290-2305
Number of pages16
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number12
DOIs
Publication statusPublished - Dec 2018

Keywords

  • asthma
  • biomarkers
  • chronic rhinosinusitis
  • drug hypersensitivity
  • food allergy

Cite this

Eguíluz-Gracia, Ibon ; Tay, Tunn Ren ; Hew, Mark ; Escribese, María Marta ; Barber, Domingo ; O'Hehir, Robyn E. ; Torres, María José. / Recent developments and highlights in biomarkers in allergic diseases and asthma. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 12. pp. 2290-2305.
@article{60ee2dbe51044eb7874f94e1534cf561,
title = "Recent developments and highlights in biomarkers in allergic diseases and asthma",
abstract = "The potential of precision medicine in allergy and asthma has only started to be explored. A significant clarification in the pathophysiology of rhinitis, chronic rhinosinusitis, asthma, food allergy and drug hypersensitivity was made in the last decade. This improved understanding led to a better classification of the distinct phenotypes and to the discovery of new drugs such as biologicals, targeting phenotype-specific mechanisms. Nevertheless, many conditions remain poorly understood such as non-eosinophilic airway diseases or non-IgE–mediated food allergy. Moreover, there is a need to predict the response to specific therapies and the outcome of drug and food provocations. The identification of patients at risk of progression towards severity is also an unmet need in order to establish adequate preventive or therapeutic measures. The implementation of precision medicine in the clinical practice requires the identification of phenotype-specific markers measurable in biological matrices. To become useful, these biomarkers need to be quantifiable by reliable systems, and in samples obtained in an easy, rapid and cost-efficient way. In the last years, significant research resources have been put in the identification of valid biomarkers for asthma and allergic diseases. This review summarizes these recent advances with focus on the biomarkers with higher clinical applicability.",
keywords = "asthma, biomarkers, chronic rhinosinusitis, drug hypersensitivity, food allergy",
author = "Ibon Egu{\'i}luz-Gracia and Tay, {Tunn Ren} and Mark Hew and Escribese, {Mar{\'i}a Marta} and Domingo Barber and O'Hehir, {Robyn E.} and Torres, {Mar{\'i}a Jos{\'e}}",
year = "2018",
month = "12",
doi = "10.1111/all.13628",
language = "English",
volume = "73",
pages = "2290--2305",
journal = "Allergy",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "12",

}

Recent developments and highlights in biomarkers in allergic diseases and asthma. / Eguíluz-Gracia, Ibon; Tay, Tunn Ren; Hew, Mark; Escribese, María Marta; Barber, Domingo; O'Hehir, Robyn E.; Torres, María José.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 12, 12.2018, p. 2290-2305.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Recent developments and highlights in biomarkers in allergic diseases and asthma

AU - Eguíluz-Gracia, Ibon

AU - Tay, Tunn Ren

AU - Hew, Mark

AU - Escribese, María Marta

AU - Barber, Domingo

AU - O'Hehir, Robyn E.

AU - Torres, María José

PY - 2018/12

Y1 - 2018/12

N2 - The potential of precision medicine in allergy and asthma has only started to be explored. A significant clarification in the pathophysiology of rhinitis, chronic rhinosinusitis, asthma, food allergy and drug hypersensitivity was made in the last decade. This improved understanding led to a better classification of the distinct phenotypes and to the discovery of new drugs such as biologicals, targeting phenotype-specific mechanisms. Nevertheless, many conditions remain poorly understood such as non-eosinophilic airway diseases or non-IgE–mediated food allergy. Moreover, there is a need to predict the response to specific therapies and the outcome of drug and food provocations. The identification of patients at risk of progression towards severity is also an unmet need in order to establish adequate preventive or therapeutic measures. The implementation of precision medicine in the clinical practice requires the identification of phenotype-specific markers measurable in biological matrices. To become useful, these biomarkers need to be quantifiable by reliable systems, and in samples obtained in an easy, rapid and cost-efficient way. In the last years, significant research resources have been put in the identification of valid biomarkers for asthma and allergic diseases. This review summarizes these recent advances with focus on the biomarkers with higher clinical applicability.

AB - The potential of precision medicine in allergy and asthma has only started to be explored. A significant clarification in the pathophysiology of rhinitis, chronic rhinosinusitis, asthma, food allergy and drug hypersensitivity was made in the last decade. This improved understanding led to a better classification of the distinct phenotypes and to the discovery of new drugs such as biologicals, targeting phenotype-specific mechanisms. Nevertheless, many conditions remain poorly understood such as non-eosinophilic airway diseases or non-IgE–mediated food allergy. Moreover, there is a need to predict the response to specific therapies and the outcome of drug and food provocations. The identification of patients at risk of progression towards severity is also an unmet need in order to establish adequate preventive or therapeutic measures. The implementation of precision medicine in the clinical practice requires the identification of phenotype-specific markers measurable in biological matrices. To become useful, these biomarkers need to be quantifiable by reliable systems, and in samples obtained in an easy, rapid and cost-efficient way. In the last years, significant research resources have been put in the identification of valid biomarkers for asthma and allergic diseases. This review summarizes these recent advances with focus on the biomarkers with higher clinical applicability.

KW - asthma

KW - biomarkers

KW - chronic rhinosinusitis

KW - drug hypersensitivity

KW - food allergy

UR - http://www.scopus.com/inward/record.url?scp=85055744173&partnerID=8YFLogxK

U2 - 10.1111/all.13628

DO - 10.1111/all.13628

M3 - Review Article

VL - 73

SP - 2290

EP - 2305

JO - Allergy

JF - Allergy

SN - 0105-4538

IS - 12

ER -